BRAF and metastatic colorectal cancer: More recently, preliminary results from the phase II NIVACOR trial demonstrated good tolerance and acceptable toxicity of a triple treatment that combined FOLFOXIRI/bevacizumab and nivolumab as first-line treatment in RAS/BRAF mutant metastatic colorectal cancer patients [26].